Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route

Buprenorphine extended‐release (BUP‐XR) formulation is a once‐monthly subcutaneous injection for the treatment of opioid use disorder (OUD). Buprenorphine undergoes extensive cytochrome P450 (CYP) 3A4 metabolism, leading to potential drug‐drug interactions (DDIs) as reported for sublingual buprenorp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharidia, Jahnavi, Howgate, Eleanor M., Laffont, Celine M., Liu, Yongzhen, Young, Malcolm A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451859/
https://www.ncbi.nlm.nih.gov/pubmed/33750027
http://dx.doi.org/10.1002/cpdd.934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451859/
https://www.ncbi.nlm.nih.gov/pubmed/33750027
http://dx.doi.org/10.1002/cpdd.934

Ejemplares similares